BIOCRYST PHARMACEUTICALS INC Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2011 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary: Biocryst Pharmaceuticals Inc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2011 to Q3 2024.
Biocryst Pharmaceuticals Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending September 30, 2024 was -$12.3M, a 65.9% increase year-over-year.
Biocryst Pharmaceuticals Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending September 30, 2024 was -$122M, a 48% increase year-over-year.
Biocryst Pharmaceuticals Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$225M, a 8.91% increase from 2022.
Biocryst Pharmaceuticals Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$247M, a 34.5% decline from 2021.
Biocryst Pharmaceuticals Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$184M, a 0.57% decline from 2020.

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)

Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$122M	-$12.3M	+$23.7M	+65.9%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-05
Q2 2024	-$146M	-$12.9M	+$62.3M	+82.9%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-06
Q1 2024	-$208M	-$35.9M	+$16.8M	+31.9%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	-$225M	-$61.2M	+$10.2M	+14.3%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-27
Q3 2023	-$235M	-$36M	+$6.59M	+15.5%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-05
Q2 2023	-$242M	-$75.2M	-$16.2M	-27.4%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-06
Q1 2023	-$226M	-$52.8M	+$21.4M	+28.9%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	-$247M	-$71.4M	-$53.7M	-303%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-27
Q3 2022	-$194M	-$42.6M	+$16.1M	+27.5%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-08
Q2 2022	-$210M	-$59M	-$15.7M	-36.4%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-07
Q1 2022	-$194M	-$74.2M	-$10.1M	-15.7%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-08
Q4 2021	-$184M	-$17.7M	+$42.8M	+70.7%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-27
Q3 2021	-$227M	-$58.8M	-$12.7M	-27.5%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-04
Q2 2021	-$214M	-$43.3M	-$4.68M	-12.1%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-05
Q1 2021	-$209M	-$64.1M	-$26.5M	-70.4%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-09
Q4 2020	-$183M	-$60.5M	-$57.9M	-2189%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-27
Q3 2020	-$125M	-$46.1M	-$8.54M	-22.7%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	-$116M	-$38.6M	-$1.12M	-2.98%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-09
Q1 2020	-$115M	-$37.6M	-$6.78M	-22%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-07
Q4 2019	-$109M	-$2.64M	+$24.7M	+90.3%	Oct 1, 2019	Dec 31, 2019	10-K	2022-02-28
Q3 2019	-$133M	-$37.6M	-$8.02M	-27.1%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-06
Q2 2019	-$125M	-$37.5M	-$19.1M	-104%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-10
Q1 2019	-$106M	-$30.8M	-$4.84M	-18.6%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-11
Q4 2018	-$101M	-$27.3M	-$7.55M	-38.2%	Oct 1, 2018	Dec 31, 2018	10-K	2021-03-01
Q3 2018	-$93.8M	-$29.6M	-$14.4M	-95.3%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-08
Q2 2018	-$79.3M	-$18.4M	-$1.52M	-9.02%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-08
Q1 2018	-$77.8M	-$26M	-$11.8M	-83%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-09
Q4 2017	-$66M	-$19.8M	-$15.2M	-336%	Oct 1, 2017	Dec 31, 2017	10-K	2020-03-13
Q3 2017	-$50.8M	-$15.1M	-$3.58M	-31%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-08
Q2 2017	-$47.2M	-$16.9M	-$615K	-3.78%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-09
Q1 2017	-$46.6M	-$14.2M	+$8.37M	+37.1%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-09
Q4 2016	-$55M	-$4.54M	+$13.8M	+75.3%	Oct 1, 2016	Dec 31, 2016	10-K	2019-03-14
Q3 2016	-$68.8M	-$11.6M	+$2.98M	+20.5%	Jul 1, 2016	Sep 30, 2016	10-Q	2017-11-08
Q2 2016	-$71.7M	-$16.3M	-$21.1M	-439%	Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-08
Q1 2016	-$50.6M	-$22.6M	-$7.55M	-50.3%	Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-08
Q4 2015	-$43.1M	-$18.3M	-$6.54M	-55.4%	Oct 1, 2015	Dec 31, 2015	10-K	2018-03-12
Q3 2015	-$36.6M	-$14.5M	-$5.8M	-66.4%	Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-08
Q2 2015	-$30.8M	$4.8M	+$19.4M		Apr 1, 2015	Jun 30, 2015	10-Q	2016-08-08
Q1 2015	-$50.2M	-$15M	-$4.89M	-48.2%	Jan 1, 2015	Mar 31, 2015	10-Q	2016-05-09
Q4 2014	-$45.3M	-$11.8M	-$6.38M	-118%	Oct 1, 2014	Dec 31, 2014	10-K	2017-02-27
Q3 2014	-$38.9M	-$8.73M	-$727K	-9.08%	Jul 1, 2014	Sep 30, 2014	10-Q	2015-11-06
Q2 2014	-$38.2M	-$14.6M	-$2.47M	-20.3%	Apr 1, 2014	Jun 30, 2014	10-Q	2015-08-07
Q1 2014	-$35.8M	-$10.1M	-$5.62M	-124%	Jan 1, 2014	Mar 31, 2014	10-Q	2015-05-08
Q4 2013	-$30.1M	-$5.43M	+$5.64M	+51%	Oct 1, 2013	Dec 31, 2013	10-K	2016-02-26
Q3 2013	-$35.8M	-$8.01M	+$1.7M	+17.5%	Jul 1, 2013	Sep 30, 2013	10-Q	2014-11-07
Q2 2013	-$37.5M	-$12.2M	+$104K	+0.85%	Apr 1, 2013	Jun 30, 2013	10-Q	2014-08-08
Q1 2013	-$37.6M	-$4.52M	+$1.53M	+25.2%	Jan 1, 2013	Mar 31, 2013	10-Q	2014-05-09
Q4 2012	-$39.1M	-$11.1M	+$2.13M	+16.2%	Oct 1, 2012	Dec 31, 2012	10-K	2015-03-02
Q3 2012	-$41.2M	-$9.7M	+$4.8M	+33.1%	Jul 1, 2012	Sep 30, 2012	10-Q	2013-11-08
Q2 2012	-$46M	-$12.3M	+$3.98M	+24.5%	Apr 1, 2012	Jun 30, 2012	10-Q	2013-08-08
Q1 2012	-$50M	-$6.04M	+$7.01M	+53.7%	Jan 1, 2012	Mar 31, 2012	10-Q	2013-05-09
Q4 2011	-$57M	-$13.2M			Oct 1, 2011	Dec 31, 2011	10-K	2014-03-10
Q3 2011		-$14.5M			Jul 1, 2011	Sep 30, 2011	10-Q	2012-11-08
Q2 2011		-$16.3M			Apr 1, 2011	Jun 30, 2011	10-Q	2012-08-08
Q1 2011		-$13.1M			Jan 1, 2011	Mar 31, 2011	10-Q	2012-05-08

* An asterisk sign (*) next to the value indicates that the value is likely invalid.